Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches

Overview

Journal Curr Allergy Asthma Rep

Specialties Allergy & Immunology
Pulmonary Medicine

Date 2018 Jun 11

PMID 29886521

Citations 37

Authors

Mirela Curin

Musa Khaitov

Alexander Karaulov

Leyla Namazova-Baranova

Raffaela Campana

Victoria Garib

Rudolf Valenta

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The aim of this article is to discuss how allergen-specific immunotherapy (AIT) can be improved through molecular approaches. We provide a summary of next-generation molecular AIT approaches and of their clinical evaluation. Furthermore, we discuss the potential of next generation molecular AIT forms for the treatment of severe manifestations of allergy and mention possible future molecular strategies for the secondary and primary prevention of allergy.

Recent Findings: AIT has important advantages over symptomatic forms of allergy treatment but its further development is limited by the quality of the therapeutic antigen preparations which are derived from natural allergen sources. The field of allergy diagnosis is currently undergoing a dramatic improvement through the use of molecular testing with defined, mainly recombinant allergens which allows high-resolution diagnosis. Several studies demonstrate that molecular testing in early childhood can predict the development of symptomatic allergy later on in life. Clinical studies indicate that molecular AIT approaches have the potential to improve therapy of allergic diseases and may be used as allergen-specific forms of secondary and eventually primary prevention for allergy.

Citing Articles

Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.

Berreiros-Hortala H, Vilchez-Pinto G, Diaz-Perales A, Garrido-Arandia M, Tome-Amat J Int J Mol Sci. 2024; 25(13).

PMID: 39000536 PMC: 11242184. DOI: 10.3390/ijms25137429.

Insect Cell-Expressed Major Ragweed Allergen Amb a 1.01 Exhibits Similar Allergenic Properties to Its Natural Counterpart from Common Ragweed Pollen.

Buzan M, Grijincu M, Zbircea L, Haidar L, Tamas T, Cotarca M Int J Mol Sci. 2024; 25(10).

PMID: 38791214 PMC: 11121294. DOI: 10.3390/ijms25105175.

Safety of subcutaneous immunotherapy with Novo-Helisen-Depot in the children: a retrospective analysis from a single center in Northern China.

Zhou Q, Liu S, Dai B, Chen L, Han L, Zhang Q Front Pediatr. 2024; 12:1370224.

PMID: 38725990 PMC: 11079119. DOI: 10.3389/fped.2024.1370224.

An Aedes-Anopheles Vaccine Candidate Supplemented with BCG Epitopes Against the Aedes and Anopheles Genera to Overcome Hypersensitivity to Mosquito Bites.

Naveed M, Ali U, Aziz T, Naveed R, Mahmood S, Khan M Acta Parasitol. 2024; 69(1):483-504.

PMID: 38194049 DOI: 10.1007/s11686-023-00771-1.

Design of an Ara h 2 hypoallergen from conformational epitopes.

Min J, Keswani T, LaHood N, Lytle I, Marini-Rapoport O, Andrieux L Clin Exp Allergy. 2024; 54(1):46-55.

PMID: 38168500 PMC: 10843581. DOI: 10.1111/cea.14433.

References

Hatzler L, Panetta V, Lau S, Wagner P, Bergmann R, Illi S . Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012; 130(4):894-901.e5. DOI: 10.1016/j.jaci.2012.05.053. View

Epstein T, Liss G, Murphy-Berendts K, Bernstein D . Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013). Ann Allergy Asthma Immunol. 2016; 116(4):354-359.e2. DOI: 10.1016/j.anai.2016.02.001. View

Giusan A, Karpov V . [Complex histaglobin and allergoid therapy of seasonal allergic diseases of the upper respiratory tract]. Vestn Otorinolaringol. 1983; (2):68-9. View

Patel D, Couroux P, Hickey P, Salapatek A, Laidler P, Larche M . Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2012; 131(1):103-9.e1-7. DOI: 10.1016/j.jaci.2012.07.028. View

Mothes N, Heinzkill M, Drachenberg K, Sperr W, Krauth M, Majlesi Y . Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003; 33(9):1198-208. DOI: 10.1046/j.1365-2222.2003.01699.x. View

Banerjee S, Weber M, Blatt K, Swoboda I, Focke-Tejkl M, Valent P . Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol. 2014; 192(10):4867-75. PMC: 4582415. DOI: 10.4049/jimmunol.1400064. View

Zuidmeer-Jongejan L, Huber H, Swoboda I, Rigby N, Versteeg S, Jensen B . Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy. Int Arch Allergy Immunol. 2015; 166(1):41-51. DOI: 10.1159/000371657. View

Larche M, Akdis C, Valenta R . Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006; 6(10):761-71. DOI: 10.1038/nri1934. View

Marsh D, Lichtenstein L, CAMPBELL D . Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology. 1970; 18(5):705-22. PMC: 1455593. View

10.

Morgenstern J, Griffith I, Brauer A, Rogers B, BOND J, Chapman M . Amino acid sequence of Fel dI, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. Proc Natl Acad Sci U S A. 1991; 88(21):9690-4. PMC: 52784. DOI: 10.1073/pnas.88.21.9690. View

11.

Roy K, Mao H, Huang S, Leong K . Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999; 5(4):387-91. DOI: 10.1038/7385. View

12.

Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth M, Valent P . Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14677-82. PMC: 521981. DOI: 10.1073/pnas.0404735101. View

13.

Spertini F, DellaCorte G, Kettner A, de Blay F, Jacobsen L, Jutel M . Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. J Allergy Clin Immunol. 2016; 138(1):162-8. DOI: 10.1016/j.jaci.2016.02.044. View

14.

Valenta R . The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002; 2(6):446-53. DOI: 10.1038/nri824. View

15.

Ferreira F, Hirtenlehner K, Jilek A, Breiteneder H, Grimm R, Hoffmann-Sommergruber K . Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med. 1996; 183(2):599-609. PMC: 2192443. DOI: 10.1084/jem.183.2.599. View

16.

Valenta R, Linhart B, Swoboda I, Niederberger V . Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy. 2011; 66(6):775-83. DOI: 10.1111/j.1398-9995.2011.02565.x. View

17.

Wickman M, Lupinek C, Andersson N, Belgrave D, Asarnoj A, Benet M . Detection of IgE Reactivity to a Handful of Allergen Molecules in Early Childhood Predicts Respiratory Allergy in Adolescence. EBioMedicine. 2017; 26:91-99. PMC: 5832567. DOI: 10.1016/j.ebiom.2017.11.009. View

18.

Klimek L, Bachert C, Lukat K, Pfaar O, Meyer H, Narkus A . Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy. 2015; 5:28. PMC: 4553934. DOI: 10.1186/s13601-015-0071-x. View

19.

Ball T, Vrtala S, Sperr W, Valent P, Susani M, Kraft D . Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J Biol Chem. 1994; 269(45):28323-8. View

20.

Slater J, Paupore E, Zhang Y, Colberg-Poley A . The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol. 1998; 102(3):469-75. DOI: 10.1016/s0091-6749(98)70137-x. View